First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
Zhang J, Ji D, Cai L, Yao H, Yan M, Wang X, Shen W, Du Y, Pang H, Lai X, Zeng H, Huang J, Sun Y, Peng X, Xu J, Yang J, Yang F, Xu T, Hu X.
Zhang J, et al.
Clin Cancer Res. 2022 Feb 15;28(4):618-628. doi: 10.1158/1078-0432.CCR-21-2827.
Clin Cancer Res. 2022.
PMID: 34844975
Clinical Trial.